vs
Alector, Inc.（ALEC）与EXELIXIS, INC.（EXEL）财务数据对比。点击上方公司名可切换其他公司
EXELIXIS, INC.的季度营收约是Alector, Inc.的96.0倍（$598.7M vs $6.2M）。EXELIXIS, INC.净利率更高（40.8% vs -597.5%，领先638.4%）。EXELIXIS, INC.同比增速更快（5.6% vs -88.5%）。过去两年EXELIXIS, INC.的营收复合增速更高（18.7% vs -37.4%）
Alector是一家临床阶段生物制药企业，专注于神经退行性疾病的免疫疗法研发，管线覆盖阿尔茨海默病、额颞叶痴呆、帕金森病等未被满足的医疗需求，主要在美国运营，与全球药企合作推进候选药物的临床试验。
Exelixis是一家总部位于美国加利福尼亚州阿拉米达的基因组学药物研发企业，专注于创新抗肿瘤药物开发，旗下产品Cometriq已获美国FDA批准用于治疗甲状腺髓样癌，在其余多种转移性癌症治疗领域也已展现出良好临床活性。
ALEC vs EXEL — 直观对比
营收规模更大
EXEL
是对方的96.0倍
$6.2M
营收增速更快
EXEL
高出94.1%
-88.5%
净利率更高
EXEL
高出638.4%
-597.5%
两年增速更快
EXEL
近两年复合增速
-37.4%
损益表 — Q4 2025 vs Q4 2026
| 指标 | | |
|---|---|---|
| 营收 | $6.2M | $598.7M |
| 净利润 | $-37.3M | $244.5M |
| 毛利率 | — | 95.6% |
| 营业利润率 | -634.4% | 39.3% |
| 净利率 | -597.5% | 40.8% |
| 营收同比 | -88.5% | 5.6% |
| 净利润同比 | -1696.9% | 74.8% |
| 每股收益（稀释后） | $-0.34 | $0.89 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALECEXEL
| Q1 26 | — | $598.7M | ||
| Q4 25 | $6.2M | $597.8M | ||
| Q3 25 | $3.3M | $568.3M | ||
| Q2 25 | $7.9M | $555.4M | ||
| Q1 25 | $3.7M | $566.8M | ||
| Q4 24 | $54.2M | — | ||
| Q3 24 | $15.3M | $539.5M | ||
| Q2 24 | $15.1M | $637.2M |
净利润ALECEXEL
| Q1 26 | — | $244.5M | ||
| Q4 25 | $-37.3M | $193.6M | ||
| Q3 25 | $-34.7M | $184.8M | ||
| Q2 25 | $-30.5M | $159.6M | ||
| Q1 25 | $-40.5M | $139.9M | ||
| Q4 24 | $-2.1M | — | ||
| Q3 24 | $-42.2M | $118.0M | ||
| Q2 24 | $-38.7M | $226.1M |
毛利率ALECEXEL
| Q1 26 | — | 95.6% | ||
| Q4 25 | — | 96.9% | ||
| Q3 25 | — | 96.6% | ||
| Q2 25 | — | 96.5% | ||
| Q1 25 | — | 96.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 96.8% | ||
| Q2 24 | — | 97.2% |
营业利润率ALECEXEL
| Q1 26 | — | 39.3% | ||
| Q4 25 | -634.4% | 39.6% | ||
| Q3 25 | -1153.6% | 37.6% | ||
| Q2 25 | -433.6% | 33.6% | ||
| Q1 25 | -1216.5% | 28.8% | ||
| Q4 24 | -13.4% | — | ||
| Q3 24 | -315.7% | 25.2% | ||
| Q2 24 | -302.4% | 43.3% |
净利率ALECEXEL
| Q1 26 | — | 40.8% | ||
| Q4 25 | -597.5% | 32.4% | ||
| Q3 25 | -1063.4% | 32.5% | ||
| Q2 25 | -387.7% | 28.7% | ||
| Q1 25 | -1101.6% | 24.7% | ||
| Q4 24 | -3.8% | — | ||
| Q3 24 | -275.2% | 21.9% | ||
| Q2 24 | -256.4% | 35.5% |
每股收益（稀释后）ALECEXEL
| Q1 26 | — | $0.89 | ||
| Q4 25 | $-0.34 | $0.69 | ||
| Q3 25 | $-0.34 | $0.65 | ||
| Q2 25 | $-0.30 | $0.55 | ||
| Q1 25 | $-0.41 | $0.47 | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $-0.43 | $0.40 | ||
| Q2 24 | $-0.40 | $0.77 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $256.0M | $1.1B |
| 总债务越低越好 | $10.0M | — |
| 股东权益账面价值 | $30.6M | $2.2B |
| 总资产 | $293.2M | $2.8B |
| 负债/权益比越低杠杆越低 | 0.33× | — |
8季度趋势，按日历期对齐
现金及短期投资ALECEXEL
| Q1 26 | — | $1.1B | ||
| Q4 25 | $256.0M | $988.5M | ||
| Q3 25 | $291.1M | $791.1M | ||
| Q2 25 | $307.3M | $1.0B | ||
| Q1 25 | $354.6M | $1.1B | ||
| Q4 24 | $413.4M | — | ||
| Q3 24 | $457.2M | $1.2B | ||
| Q2 24 | $503.3M | $1.0B |
总债务ALECEXEL
| Q1 26 | — | — | ||
| Q4 25 | $10.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ALECEXEL
| Q1 26 | — | $2.2B | ||
| Q4 25 | $30.6M | $2.2B | ||
| Q3 25 | $57.7M | $2.0B | ||
| Q2 25 | $71.2M | $2.1B | ||
| Q1 25 | $94.6M | $2.2B | ||
| Q4 24 | $126.8M | — | ||
| Q3 24 | $118.9M | $2.3B | ||
| Q2 24 | $150.6M | $2.1B |
总资产ALECEXEL
| Q1 26 | — | $2.8B | ||
| Q4 25 | $293.2M | $2.8B | ||
| Q3 25 | $335.3M | $2.7B | ||
| Q2 25 | $356.4M | $2.8B | ||
| Q1 25 | $408.3M | $2.9B | ||
| Q4 24 | $468.3M | — | ||
| Q3 24 | $516.0M | $3.0B | ||
| Q2 24 | $570.7M | $2.8B |
负债/权益比ALECEXEL
| Q1 26 | — | — | ||
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.08× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-41.7M | $333.5M |
| 自由现金流经营现金流 - 资本支出 | — | $332.4M |
| 自由现金流率自由现金流/营收 | — | 55.5% |
| 资本支出强度资本支出/营收 | 0.0% | 0.2% |
| 现金转化率经营现金流/净利润 | — | 1.36× |
| 过去12个月自由现金流最近4个季度 | — | $875.8M |
8季度趋势，按日历期对齐
经营现金流ALECEXEL
| Q1 26 | — | $333.5M | ||
| Q4 25 | $-41.7M | $290.3M | ||
| Q3 25 | $-32.5M | $49.0M | ||
| Q2 25 | $-49.0M | $211.4M | ||
| Q1 25 | $-60.8M | $240.3M | ||
| Q4 24 | $-55.0M | — | ||
| Q3 24 | $-50.7M | $271.3M | ||
| Q2 24 | $-62.8M | $119.5M |
自由现金流ALECEXEL
| Q1 26 | — | $332.4M | ||
| Q4 25 | — | $288.8M | ||
| Q3 25 | $-32.5M | $46.2M | ||
| Q2 25 | $-49.1M | $208.5M | ||
| Q1 25 | $-60.8M | $236.3M | ||
| Q4 24 | $-55.2M | — | ||
| Q3 24 | $-50.9M | $263.1M | ||
| Q2 24 | $-63.1M | $113.0M |
自由现金流率ALECEXEL
| Q1 26 | — | 55.5% | ||
| Q4 25 | — | 48.3% | ||
| Q3 25 | -997.6% | 8.1% | ||
| Q2 25 | -623.0% | 37.5% | ||
| Q1 25 | -1655.0% | 41.7% | ||
| Q4 24 | -101.8% | — | ||
| Q3 24 | -332.1% | 48.8% | ||
| Q2 24 | -418.6% | 17.7% |
资本支出强度ALECEXEL
| Q1 26 | — | 0.2% | ||
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.3% | 0.5% | ||
| Q2 25 | 0.1% | 0.5% | ||
| Q1 25 | 0.5% | 0.7% | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 1.4% | 1.5% | ||
| Q2 24 | 2.2% | 1.0% |
现金转化率ALECEXEL
| Q1 26 | — | 1.36× | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | — | 1.72× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.30× | ||
| Q2 24 | — | 0.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
